Northwest Biotherapeutics (NWBO) 4.39 $NWBO
5 Stocks We're Staying Away From in 2016
Brian Feroldi, Selena Maranjian, Sean Williams, Brian Stoffel, and Jason Hall, The Motley Fool - Motley Fool - 1 hr 38 mins ago
Image by PeteLinforth via Pixabay. Investing in the stock market is one of the best wealth-building tools available to individual investors, as the returns provided from the market's best growth companies can be jaw dropping . Still, finding those...
PM: 86.92 (-2.16), NWBO: 4.39 (+0.18), GLD: 102.04 (+1.54), BBY: 29.04 (-0.76), SHLD: 19.46 (+0.10), PDLI: 3.79 (-0.03)
Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 21.57 (+0.79), NWBO: 4.39 (+0.18)
Where We Are Headed - Featured Research on Bancorp Inc., Northwest Biotherapeutics, Xerium Technologies, and BioPharmX
ACCESSWIRE - Wed Dec 16, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Bancorp Inc. (NASDAQ: TBBK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Xerium Technologies Inc. (NYSE: XRM) and BioPharmX Corp (NYSE: BPMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 4.39 (+0.18), XRM: 10.70 (-0.35), TBBK: 6.43 (-0.32), BPMX: 1.56 (-0.05)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
Business Wire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 4.39 (+0.18), TSRO: 49.92 (-0.94), CTMX: 20.65 (-0.04), NK: 15.67 (unch), CNCR: 28.24 (-0.01), SRNE: 7.81 (-0.30), XNCR: 15.06 (+0.26), ONTY: 2.20 (+0.03), CYAD: 50.40 (+0.91)
BUYINS.NET: NWBO SqueezeTrigger Price is $4.05. There is $52,181,556 That Short Sellers Still Need To Cover.
M2 - Tue Dec 15, 9:48AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Northwest Biotherapeutics Inc (NASDAQ:NWBO) in real time and just received an alert that NWBO is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 12852600 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $4.05. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
NWBO: 4.39 (+0.18)
NW Bio Statement Regarding Appointments
PR Newswire - Tue Dec 08, 7:15AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, responded today to shareholder questions about appointments relating to the Company's Board, and an independent investigation of recent allegations in an anonymous internet report and a derivative lawsuit which cites the anonymous internet report.
NWBO: 4.39 (+0.18)
NW Bio Announces Establishment of Special Committee And Law Firm To Conduct Independent Investigation of Recent Allegations
PR Newswire - Tue Dec 08, 7:15AM CST
Northwest Biotherapeutics (NASDAQ: NWBO)("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Special Committee has been established by the Board of Directors to oversee an independent investigation of recent allegations in an anonymous internet report and a derivative lawsuit which cites the anonymous internet report. The Special Committee has selected a highly experienced independent law firm to lead an Investigation Team to conduct the investigation.
NWBO: 4.39 (+0.18)
Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics
at The Street - Wed Dec 02, 5:11AM CST
TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.
NWBO: 4.39 (+0.18), BMRN: 104.44 (+3.80), AVXL: 7.49 (+0.03), THLD: 0.51 (-0.03)
NW Bio Plans to Expand Board, Welcomes Woodford's Call For Independent Investigation Of Allegations In Anonymous Internet Report
PR Newswire - Mon Nov 30, 6:15AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" , a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Board is committed to adding an additional independent director, and the Company welcomes Neil Woodford's call for an independent investigation of allegations in a recent anonymous internet report on NW Bio. The Company's Board is under way on both initiatives.
NWBO: 4.39 (+0.18)
Equity Market Movement at a Glance - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Ekso Bionics Holdings, and Medical Marijuana
ACCESSWIRE - Tue Nov 24, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO),Elite Pharmaceuticals Inc. (OTC: ELTP), Ekso Bionics Holdings Inc. (OTC: EKSO) and Medical Marijuana Inc. (OTC: MJNA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 4.39 (+0.18)
Glancy, Prongay & Murray LLP Commences Investigation on Behalf of Northwest Biotherapeutics, Inc. Investors
Business Wire - Mon Nov 23, 7:59PM CST
Glancy, Prongay & Murray LLP ("GPM" announces that it is investigating potential claims on behalf of investors of Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("Northwest Bio" or "the Company" and whether the officers and directors complied with their legal obligations to the Company and its shareholders.
NWBO: 4.39 (+0.18)
3 Stocks I Would Avoid at All Costs
Steve Symington, Jason Hall, and Brian Feroldi, The Motley Fool - Motley Fool - Mon Nov 16, 6:01PM CST
It seems obvious to say the key to beating the market is finding great stocks to buy and hold over the long term. But equally important to achieving that goal -- and arguably just as difficult -- is knowing which stocks to avoid along the way. We...
NWBO: 4.39 (+0.18), CLF: 1.57 (-0.02), ZNGA: 2.64 (+0.04)
The Price Data Tells the Story - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Barrett Business Services and Ekso Bionics Holdings
ACCESSWIRE - Mon Nov 16, 7:02AM CST
NEW YORK, NY ACCESSWIRE / November 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc (NASDAQ: NWBO),Elite Pharmaceuticals Inc (OTC: ELTP), Barrett Business Services Inc (NASDAQ: BBSI) and Ekso Bionics Holdings Inc (OTC: EKSO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 4.39 (+0.18), BBSI: 44.85 (-0.13)
Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio
at The Street - Fri Nov 13, 8:36AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 61.45 (-0.55), ZFGN: 7.15 (-0.02), NWBO: 4.39 (+0.18), ZSPH: 89.98 (+0.06), SPHS: 1.73 (-0.01), RLYP: 27.92 (+0.25)
Perception, Opportunity in Volatility - Research on Vera Bradley, PositiveID, NanoTech Entertainment and Northwest Biotherapeutics
ACCESSWIRE - Mon Nov 09, 7:15AM CST
NEW YORK, NY / ACCESSWIRE / November 9, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vera Bradley Inc. (NASDAQ: VRA),PositiveID Corp (OTC: PSID), NanoTech Entertainment Inc. (OTC: NTEK) and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 4.39 (+0.18), VRA: 16.25 (+0.09)
Technical Coverage on Healthcare Sector - Research on Uniqure, CytomX Therapeutics, Northwest Biotherapeutics and Healthways
ACCESSWIRE - Wed Nov 04, 7:11AM CST
NEW YORK, NY / ACCESSWIRE / November 4, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Uniqure NV (NASDAQ: QURE), CytomX Therapeutics Inc. (NASDAQ: CTMX), Northwest Biotherapeutics Inc. (NASDAQ: NWBO) and Healthways Inc. (NASDAQ: HWAY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
NWBO: 4.39 (+0.18), CTMX: 20.65 (-0.04), QURE: 16.00 (-1.40), HWAY: 12.63 (-0.34)
Bragar, Eagel & Squire, P.C. Is Investigating the Officers and Directors of Northwest Biotherapeutics on Behalf of Stockholders
Business Wire - Mon Nov 02, 5:53PM CST
Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) investors concerning whether the company's officers and board of directors violated their fiduciary duties.
NWBO: 4.39 (+0.18)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Northwest Biotherapeutics, Inc. and Lead Plaintiff Deadline October 26, 2015
ACCESSWIRE - Fri Oct 23, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 23, 2015 / Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the District of Maryland on behalf of those who purchased securities of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company" (NasdaqCM: NWBO), during the period between March 8, 2013 and August 20, 2015 inclusive. (the "Class Period" .
NWBO: 4.39 (+0.18)
5 Stocks We're Staying Away From in 2016
Brian Feroldi, Selena Maranjian, Sean Williams, Brian Stoffel, and Jason Hall, The Motley Fool - Motley Fool - 1 hr 38 mins ago
Image by PeteLinforth via Pixabay. Investing in the stock market is one of the best wealth-building tools available to individual investors, as the returns provided from the market's best growth companies can be jaw dropping . Still, finding those...
PM: 86.92 (-2.16), NWBO: 4.39 (+0.18), GLD: 102.04 (+1.54), BBY: 29.04 (-0.76), SHLD: 19.46 (+0.10), PDLI: 3.79 (-0.03)
Metastatic Ovarian Cancer Pipeline Review, H2 2015 - 9 Companies & 13 Drug Profiles
M2 - Thu Dec 17, 4:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/tp9jps/metastatic) has announced the addition of the "Metastatic Ovarian Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cellceutix Corporation - Eisai Co., Ltd. - F. Hoffmann-La Roche Ltd. - Immune Design Corp. - Millennium Pharmaceuticals, Inc. - Natco Pharma Limited - Northwest Biotherapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - VG Life Sciences, Inc. Drug Profiles - DCVax-Direct - DCVax-L - Drugs for Metastatic Ovarian Cancer - E-7449 - emactuzumab - G-305 - hydroxychloroquine sorafenib tosylate - KM-3174 - LV-305 - NRCAN-019 - orteronel - SM-276001 - Vaccine for Oncology For more information visit http://www.researchandmarkets.com/research/tp9jps/metastatic
IMDZ: 21.57 (+0.79), NWBO: 4.39 (+0.18)
Where We Are Headed - Featured Research on Bancorp Inc., Northwest Biotherapeutics, Xerium Technologies, and BioPharmX
ACCESSWIRE - Wed Dec 16, 7:23AM CST
NEW YORK, NY / ACCESSWIRE / December 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Bancorp Inc. (NASDAQ: TBBK), Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Xerium Technologies Inc. (NYSE: XRM) and BioPharmX Corp (NYSE: BPMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 4.39 (+0.18), XRM: 10.70 (-0.35), TBBK: 6.43 (-0.32), BPMX: 1.56 (-0.05)
Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
Business Wire - Wed Dec 16, 6:00AM CST
Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing cancer immunotherapy treatments and finding new ways to use the body's immune system to fight cancer.
NWBO: 4.39 (+0.18), TSRO: 49.92 (-0.94), CTMX: 20.65 (-0.04), NK: 15.67 (unch), CNCR: 28.24 (-0.01), SRNE: 7.81 (-0.30), XNCR: 15.06 (+0.26), ONTY: 2.20 (+0.03), CYAD: 50.40 (+0.91)
BUYINS.NET: NWBO SqueezeTrigger Price is $4.05. There is $52,181,556 That Short Sellers Still Need To Cover.
M2 - Tue Dec 15, 9:48AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring Northwest Biotherapeutics Inc (NASDAQ:NWBO) in real time and just received an alert that NWBO is crossing above its primary SqueezeTrigger Price, the price that a short squeeze can start in any stock. There are 12852600 shares that have been shorted at the volume weighted average SqueezeTrigger Price of $4.05. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com .
NWBO: 4.39 (+0.18)
NW Bio Statement Regarding Appointments
PR Newswire - Tue Dec 08, 7:15AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, responded today to shareholder questions about appointments relating to the Company's Board, and an independent investigation of recent allegations in an anonymous internet report and a derivative lawsuit which cites the anonymous internet report. NWBO: 4.39 (+0.18)
NW Bio Announces Establishment of Special Committee And Law Firm To Conduct Independent Investigation of Recent Allegations
PR Newswire - Tue Dec 08, 7:15AM CST
Northwest Biotherapeutics (NASDAQ: NWBO)("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that a Special Committee has been established by the Board of Directors to oversee an independent investigation of recent allegations in an anonymous internet report and a derivative lawsuit which cites the anonymous internet report. The Special Committee has selected a highly experienced independent law firm to lead an Investigation Team to conduct the investigation. NWBO: 4.39 (+0.18)
Biotech Stock Mailbag: Anavex, Northwest Bio, Threshold Therapeutics
at The Street - Wed Dec 02, 5:11AM CST
TheStreet's biotech columnist Adam Feuerstein answers readers' questions about health care.
NWBO: 4.39 (+0.18), BMRN: 104.44 (+3.80), AVXL: 7.49 (+0.03), THLD: 0.51 (-0.03)
NW Bio Plans to Expand Board, Welcomes Woodford's Call For Independent Investigation Of Allegations In Anonymous Internet Report
PR Newswire - Mon Nov 30, 6:15AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the Board is committed to adding an additional independent director, and the Company welcomes Neil Woodford's call for an independent investigation of allegations in a recent anonymous internet report on NW Bio. The Company's Board is under way on both initiatives. NWBO: 4.39 (+0.18)
Equity Market Movement at a Glance - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Ekso Bionics Holdings, and Medical Marijuana
ACCESSWIRE - Tue Nov 24, 7:10AM CST
NEW YORK, NY / ACCESSWIRE / November 24, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO),Elite Pharmaceuticals Inc. (OTC: ELTP), Ekso Bionics Holdings Inc. (OTC: EKSO) and Medical Marijuana Inc. (OTC: MJNA). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 4.39 (+0.18)
Glancy, Prongay & Murray LLP Commences Investigation on Behalf of Northwest Biotherapeutics, Inc. Investors
Business Wire - Mon Nov 23, 7:59PM CST
Glancy, Prongay & Murray LLP ("GPM"
announces that it is investigating potential claims on behalf of investors of Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("Northwest Bio" or "the Company" and whether the officers and directors complied with their legal obligations to the Company and its shareholders. NWBO: 4.39 (+0.18)
3 Stocks I Would Avoid at All Costs
Steve Symington, Jason Hall, and Brian Feroldi, The Motley Fool - Motley Fool - Mon Nov 16, 6:01PM CST
It seems obvious to say the key to beating the market is finding great stocks to buy and hold over the long term. But equally important to achieving that goal -- and arguably just as difficult -- is knowing which stocks to avoid along the way. We...
NWBO: 4.39 (+0.18), CLF: 1.57 (-0.02), ZNGA: 2.64 (+0.04)
The Price Data Tells the Story - Research on Northwest Biotherapeutics, Elite Pharmaceuticals, Barrett Business Services and Ekso Bionics Holdings
ACCESSWIRE - Mon Nov 16, 7:02AM CST
NEW YORK, NY ACCESSWIRE / November 16, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Northwest Biotherapeutics Inc (NASDAQ: NWBO),Elite Pharmaceuticals Inc (OTC: ELTP), Barrett Business Services Inc (NASDAQ: BBSI) and Ekso Bionics Holdings Inc (OTC: EKSO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 4.39 (+0.18), BBSI: 44.85 (-0.13)
Biotech Stock Mailbag: Relypsa, Sophiris, Bluebird, Zafgen, NW Bio
at The Street - Fri Nov 13, 8:36AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 61.45 (-0.55), ZFGN: 7.15 (-0.02), NWBO: 4.39 (+0.18), ZSPH: 89.98 (+0.06), SPHS: 1.73 (-0.01), RLYP: 27.92 (+0.25)
Perception, Opportunity in Volatility - Research on Vera Bradley, PositiveID, NanoTech Entertainment and Northwest Biotherapeutics
ACCESSWIRE - Mon Nov 09, 7:15AM CST
NEW YORK, NY / ACCESSWIRE / November 9, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vera Bradley Inc. (NASDAQ: VRA),PositiveID Corp (OTC: PSID), NanoTech Entertainment Inc. (OTC: NTEK) and Northwest Biotherapeutics Inc. (NASDAQ: NWBO). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
NWBO: 4.39 (+0.18), VRA: 16.25 (+0.09)
Technical Coverage on Healthcare Sector - Research on Uniqure, CytomX Therapeutics, Northwest Biotherapeutics and Healthways
ACCESSWIRE - Wed Nov 04, 7:11AM CST
NEW YORK, NY / ACCESSWIRE / November 4, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Uniqure NV (NASDAQ: QURE), CytomX Therapeutics Inc. (NASDAQ: CTMX), Northwest Biotherapeutics Inc. (NASDAQ: NWBO) and Healthways Inc. (NASDAQ: HWAY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full research reports are being made available to the public on a complimentary basis.
NWBO: 4.39 (+0.18), CTMX: 20.65 (-0.04), QURE: 16.00 (-1.40), HWAY: 12.63 (-0.34)
Bragar, Eagel & Squire, P.C. Is Investigating the Officers and Directors of Northwest Biotherapeutics on Behalf of Stockholders
Business Wire - Mon Nov 02, 5:53PM CST
Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) investors concerning whether the company's officers and board of directors violated their fiduciary duties.
NWBO: 4.39 (+0.18)
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action against Northwest Biotherapeutics, Inc. and Lead Plaintiff Deadline October 26, 2015
ACCESSWIRE - Fri Oct 23, 7:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 23, 2015 / Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court for the District of Maryland on behalf of those who purchased securities of Northwest Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the "Company"
(NasdaqCM: NWBO), during the period between March 8, 2013 and August 20, 2015 inclusive. (the "Class Period" . NWBO: 4.39 (+0.18)
